GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

Mercer reports that smaller employers – those with 50-499 employees – are facing increases as high as 9% if they don't take action to lower them. GLP-1 drugs, including popular names like Ozempic and ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

Novo blamed the GLP-1 sales blip primarily on negative adjustments ... “We feel an obligation for taking action on this so patients who seek treatment and perhaps believe they’re getting ...

Data quickly showed that GLP-1 had a role in obesity too ... I think that we now have a very good understanding of the mechanism of action of these drugs on obesity. We have yet to see this ...

Ω* The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, the MindBody GLP-1 System could holistically and sustainably ...

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

Both medications are GLP-1 agonists, used to treat diabetes and ... Moreover, the price action in the stock throughout 2024 may suggest that it's a little overbought. It's hard to imagine a ...